Asset
NIVOLUMAB
Replimune Group Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06581406 | phase2_3 | recruiting | 2024-12-17 | 2030-01-01 | Replimune, Inc. | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| NCT03767348 | phase2 | active_not_recruiting | 2017-09-20 | 2028-06-01 | Replimune, Inc. | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) |
| NCT04336241 | phase1 | active_not_recruiting | 2019-10-17 | 2026-10-31 | Replimune, Inc. | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors |
| NCT04735978 | phase1 | active_not_recruiting | 2020-12-29 | 2026-11-30 | Replimune, Inc. | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours |
| NCT05743270 | phase2 | withdrawn | 2024-01-30 | 2026-03-01 | Replimune, Inc. | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN |
FDA applications (0)
This company has no applications containing this asset.